Literature DB >> 23295697

Mucosal protection by phosphatidylcholine.

Wolfgang Stremmel1, Robert Ehehalt, Sabine Staffer, Sabine Stoffels, Andrea Mohr, Max Karner, Annika Braun.   

Abstract

The colonic mucus serves a first barrier towards invasion of commensal bacteria in stools to prevent inflammation. One essential component of intestinal mucus is phosphatidylcholine (PC) which represents more than 90% of the phospholipids in mucus indicative for a selective transport of PC into this compartment. It is arranged in lamellar structures as surfactant-like particles which provide a hydrophobic surface on top of the hydrated mucus gel to prevent the invasion of bacteria from intestinal lumen. In ulcerative colitis (UC), the mucus PC content is reduced by 70%, irrespective of the state of inflammation. Thus, it could represent an intrinsic primary pathogenetic condition predisposing to bacterial invasion and the precipitation of inflammation. Since PC was shown to be mainly secreted by the ileal mucosa from where it is assumed to move distally to the colon, the PC content along the colonic wall towards the rectum gradually thins, with the least PC content in the rectum. This explains the start of the clinical manifestation of UC in the rectum and the expansion from there to the upper parts of the colon. In three clinical trials, when missing mucus PC in UC was supplemented by an oral, delayed release PC preparation, the inflammation improved and even resolved after a 3-month treatment course. The data indicate the essential role of the mucus PC content for protection against inflammation in colon.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295697     DOI: 10.1159/000342729

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  18 in total

1.  Protective effects of L-alpha-glycerylphosphorylcholine on ischaemia-reperfusion-induced inflammatory reactions.

Authors:  Tünde Tőkés; Eszter Tuboly; Gabriella Varga; László Major; Miklós Ghyczy; József Kaszaki; Mihály Boros
Journal:  Eur J Nutr       Date:  2014-03-28       Impact factor: 5.614

2.  Surfactant inhibits ATP-induced release of interleukin-1β via nicotinic acetylcholine receptors.

Authors:  Sören Backhaus; Anna Zakrzewicz; Katrin Richter; Jelena Damm; Sigrid Wilker; Gabriele Fuchs-Moll; Mira Küllmar; Andreas Hecker; Ivan Manzini; Clemens Ruppert; J Michael McIntosh; Winfried Padberg; Veronika Grau
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

3.  Novel de novo synthesized phosphate carrier compound ABA-PEG20k-Pi20 suppresses collagenase production in Enterococcus faecalis and prevents colonic anastomotic leak in an experimental model.

Authors:  M Wiegerinck; S K Hyoju; J Mao; A Zaborin; C Adriaansens; E Salzman; N H Hyman; O Zaborina; H van Goor; J C Alverdy
Journal:  Br J Surg       Date:  2018-04-16       Impact factor: 6.939

4.  Protective effects of citicoline on TNBS-induced experimental colitis in rats.

Authors:  Rauf Onur Ek; Mukadder Serter; Kemal Ergin; Serpil Cecen; Cengiz Unsal; Yuksel Yildiz; Mehmet D Bilgin
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 5.  Intestinal barrier in inflammatory bowel disease.

Authors:  Lena Antoni; Sabine Nuding; Jan Wehkamp; Eduard F Stange
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  Metabolic mapping of A3 adenosine receptor agonist MRS5980.

Authors:  Zhong-Ze Fang; Dilip K Tosh; Naoki Tanaka; Haina Wang; Kristopher W Krausz; Robert O'Connor; Kenneth A Jacobson; Frank J Gonzalez
Journal:  Biochem Pharmacol       Date:  2015-07-23       Impact factor: 5.858

Review 7.  Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges.

Authors:  Marcel Vetter; Markus F Neurath
Journal:  Therap Adv Gastroenterol       Date:  2017-09-05       Impact factor: 4.409

8.  The Detergent Effect of Mesalazine Interferes with Phosphatidylcholine Binding to Mucin 2.

Authors:  Wolfgang Stremmel; Simone Staffer; Sven Gehrke
Journal:  Inflamm Intest Dis       Date:  2018-10-18

9.  Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors.

Authors:  Wolfgang Stremmel; Simone Staffer; Nicole Stuhrmann; Hongying Gan-Schreier; Annika Gauss; Nina Burger; Daniel Hornuss
Journal:  Inflamm Intest Dis       Date:  2018-03-06

Review 10.  The intestinal barrier: a fundamental role in health and disease.

Authors:  Maaike Vancamelbeke; Séverine Vermeire
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-06-26       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.